
171.52 Delayed Data As of Sep 22 | ![]() Today’s Change | 169.85 Today|||52-Week Range 242.97 | -27.83% Year-to-Date |
The 24 analysts offering 12-month price forecasts for Alnylam Pharmaceuticals Inc have a median target of 250.00, with a high estimate of 405.00 and a low estimate of 134.00. The median estimate represents a +45.76% increase from the last price of 171.52.
The current consensus among 27 polled investment analysts is to Buy stock in Alnylam Pharmaceuticals Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.